A MODERN APPROACH TO THE TREATMENT AND PROPHYLAXIS OF VENOUS THROMBOEMBOLISM. PART II
https://doi.org/10.24884/2072-6716-2017-18-4-60-65
Abstract
The article highlights the burden of the venous thromboembolism (VTE) in clinical practice as one of the most frequent cause of cardiovascular death and disabling embolic stroke worldwide. The author compares the traditional use of VKA antagonists and new class of oral anticoagulants — direct thrombin and factor Xa inhibitors for VTE treatment and prevention. The results of most significant randomized clinical trials in VTE area and latest international guidelines are also discussed.
About the Author
V. I. Shalnev
North-Western State Medical University named after I. I. Mechnikov, St. Petersburg
Russian Federation
Russian Federation
References
1. Шальнев В. И. Современная тактика лечения и профилактики венозных тромбозов и тромбоэмболий. Роль новых пероральных антикоагулянтов. Часть I. // Скорая медицинская помощь. 2017. № 2. С. 37–44. [Shalnev V. I. Skoraya meditsinskaya pomosch, 2017, No 2, рр. 37–44. (In Russ.)]
2. Schulman S., Kakkar A. K., Goldhaber S. Z. et al. for the RE-COVER and RE-COVER II Investigators. Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis. Circulation, 2014, Vol. 129, рр. 764–772.
3. Agnelli G., Buller H. R., Cohen A. et al. for the AMLIFY Investigators. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. New Engl. J. Med., 2013, Vol. 369, рр. 799–807.
4. The EINSTEIN-PE Investigators. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. New Engl. J. Med., 2012, Vol. 366, рр. 1287–1297.
5. The EINSTEIN Investigators. Oral Rivaroxaban for Symptomatic Venous Thromboembolism. New Engl. J. Med., 2010, Vol. 363, рр. 2499–510.
6. Konstantinides S. V., Torbicki A., Agnelli G. et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur. Heart J., 2014, Vol. 35, рр. 3033–3069.
7. Martinez C., Cohen A. T., Bamber L., Rietbrock S. Epidemiology of first and recurrent venous thromboembolism: a population–based cohort study in patients without active cancer. J. Thromb Haemost., 2014, Vol. 112, рр. 255–263.
8. Cohen A. T., Katholing A., Rietbrock S. et al. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. J. Thromb Haemost., 2017, Vol. 117, рр. 57–65.
9. Kearon C., Akl E. A., Ornelas J. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest, 2016, Vol. 149, рр. 315–352.
10. Schulman S., Kearon C., Kakkar A. K. et al. for the RE–MEDI and RE–SONATE Investigators. Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism. New Engl. J. Med., 2013, Vol. 368, рр. 709–718.
11. Agnelli G., Buller H. R., Cohen A. et al. Apixaban for Extended Treatment of Venous Thromboembolism. New Engl. J. Med., 2013, Vol. 368, рр. 699–708.
12. Weitz J. I., Lensing A. W., Prins M. H. et al. for the EINSTEIN CHOICE Investigators. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. New Engl. J. Med., 2017, Vol. 376, рр. 1211–1222.
13. Raskob G. E., Spyropoulos A. C., Zrubek J. et al. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. J. Thromb Haemost., 2016, Vol. 115, рр. 1240–1248.
14. Eikelboom J. W., Connolly S. J., Bosch J. et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N. Engl. J. Med., 2017, Vol. 377, рр. 1319–1327.
15. Cannon C. P., Bhatt D. L., Oldgren J. et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N. Engl. J. Med., 2017, Vol. 377, рр. 1513–1524.
Review
For citations:
Shalnev V.I. A MODERN APPROACH TO THE TREATMENT AND PROPHYLAXIS OF VENOUS THROMBOEMBOLISM. PART II. EMERGENCY MEDICAL CARE. 2017;18(4):60-65. (In Russ.) https://doi.org/10.24884/2072-6716-2017-18-4-60-65
Views:
491
Email this article 